{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:56:21Z","timestamp":1790052981550,"version":"4.0.1"},"reference-count":71,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Scientific Research\u2014FNRS","award":["J.0143.20F CDR"],"award-info":[{"award-number":["J.0143.20F CDR"]}]},{"name":"Scientific Research\u2014FNRS","award":["2022-J1813300-227561"],"award-info":[{"award-number":["2022-J1813300-227561"]}]},{"name":"Scientific Research\u2014FNRS","award":["2023-J1813300-229649"],"award-info":[{"award-number":["2023-J1813300-229649"]}]},{"name":"Fondation Jaumotte-Demoulin (Universit\u00e9 libre de Bruxelles)","award":["J.0143.20F CDR"],"award-info":[{"award-number":["J.0143.20F CDR"]}]},{"name":"Fondation Jaumotte-Demoulin (Universit\u00e9 libre de Bruxelles)","award":["2022-J1813300-227561"],"award-info":[{"award-number":["2022-J1813300-227561"]}]},{"name":"Fondation Jaumotte-Demoulin (Universit\u00e9 libre de Bruxelles)","award":["2023-J1813300-229649"],"award-info":[{"award-number":["2023-J1813300-229649"]}]},{"name":"King Baudouin Foundation","award":["J.0143.20F CDR"],"award-info":[{"award-number":["J.0143.20F CDR"]}]},{"name":"King Baudouin Foundation","award":["2022-J1813300-227561"],"award-info":[{"award-number":["2022-J1813300-227561"]}]},{"name":"King Baudouin Foundation","award":["2023-J1813300-229649"],"award-info":[{"award-number":["2023-J1813300-229649"]}]},{"name":"Fondation Rose et Jean Hoguet (Universit\u00e9 libre de Bruxelles)","award":["J.0143.20F CDR"],"award-info":[{"award-number":["J.0143.20F CDR"]}]},{"name":"Fondation Rose et Jean Hoguet (Universit\u00e9 libre de Bruxelles)","award":["2022-J1813300-227561"],"award-info":[{"award-number":["2022-J1813300-227561"]}]},{"name":"Fondation Rose et Jean Hoguet (Universit\u00e9 libre de Bruxelles)","award":["2023-J1813300-229649"],"award-info":[{"award-number":["2023-J1813300-229649"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Thyroid cancer is the most prevalent endocrine malignancy, and papillary thyroid carcinoma (PTC) is the most common type of thyroid malignancy. While PTC generally has a favorable prognosis, a subset dedifferentiates into aggressive forms. However, the molecular mechanisms responsible for aggressiveness and dedifferentiation are still poorly understood. We previously showed that HMGA2, a non-histone architectural transcription factor overexpressed in PTC, is involved in cell invasion. This study aimed to further analyze the role of HMGA2 in PTC tumorigenesis by exploring the expression of thyroid-specific and EMT-related genes following HMGA2 knockdown in thyroid cancer cell lines. Then, the clinical relevance of our data was evaluated in vivo. HMGA2 silencing did not modulate the expression of EMT related genes but led to the increased expression of thyroid differentiation genes. Our data also suggest that the MAPK pathway induces thyroid cell dedifferentiation through HMGA2. On the other hand, forskolin, promoting thyroid differentiation, decreased HMGA2 expression. The negative correlations between HMGA2 and thyroid-specific gene expressions were confirmed in a transgenic mouse model of PTC and in human PTC. Finally, we showed that HMGA2 inhibition by suramin reduced cell invasion and induced differentiation expression in vitro, indicating a new therapeutic strategy for treating thyroid cancer.<\/jats:p>","DOI":"10.3390\/ijms26041643","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T11:14:41Z","timestamp":1739531681000},"page":"1643","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["HMGA2 Overexpression in Papillary Thyroid Cancer Promotes Thyroid Cell Dedifferentiation and Invasion, and These Effects Are Counteracted by Suramin"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4527-4702","authenticated-orcid":false,"given":"Cindy","family":"Van Branteghem","sequence":"first","affiliation":[{"name":"IRIBHM\u2014Jacques E. Dumont, Universit\u00e9 Libre de Bruxelles, 1070 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3423-5801","authenticated-orcid":false,"given":"Nicolas","family":"Henry","sequence":"additional","affiliation":[{"name":"IRIBHM\u2014Jacques E. Dumont, Universit\u00e9 Libre de Bruxelles, 1070 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ligia","family":"Craciun","sequence":"additional","affiliation":[{"name":"Anatomie Pathologique, H\u00f4pital Universitaire de Bruxelles, Universit\u00e9 Libre de Bruxelles, 1070 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Maenhaut","sequence":"additional","affiliation":[{"name":"IRIBHM\u2014Jacques E. Dumont, Universit\u00e9 Libre de Bruxelles, 1070 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Kruger, E., Toraih, E.A., Hussein, M.H., Shehata, S.A., Waheed, A., Fawzy, M.S., and Kandil, E. (2022). Thyroid Carcinoma: A Review for 25 Years of Environmental Risk Factors Studies. Cancers, 14.","DOI":"10.3390\/cancers14246172"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1038\/modpathol.2008.10","article-title":"Thyroid carcinoma: Molecular pathways and therapeutic targets","volume":"21","author":"Nikiforov","year":"2008","journal-title":"Mod. Pathol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.7150\/thno.57689","article-title":"Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS","volume":"11","author":"Oh","year":"2021","journal-title":"Theranostics"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Mansoori, B., Mohammadi, A., Ditzel, H.J., Duijf, P.H.G., Khaze, V., Gjerstorff, M.F., and Baradaran, B. (2021). HMGA2 as a Critical Regulator in Cancer Development. Genes, 12.","DOI":"10.3390\/genes12020269"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Parisi, S., Piscitelli, S., Passaro, F., and Russo, T. (2020). HMGA Proteins in Stemness and Differentiation of Embryonic and Adult Stem Cells. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21010362"},{"key":"ref_6","first-page":"775","article-title":"Oncological role of HMGA2 (Review)","volume":"55","author":"Zhang","year":"2019","journal-title":"Int. J. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/gcc.20505","article-title":"Upregulation of HMGA2 in thyroid carcinomas: A novel molecular marker to distinguish between benign and malignant follicular neoplasias","volume":"47","author":"Belge","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"10343","DOI":"10.18632\/oncotarget.23130","article-title":"Thyroid follicular adenomas and carcinomas: Molecular profiling provides evidence for a continuous evolution","volume":"9","author":"Dom","year":"2017","journal-title":"Oncotarget"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.ejca.2008.02.039","article-title":"HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias","volume":"44","author":"Chiappetta","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/cen.13853","article-title":"Diagnostic performance of HMGA2 gene expression for differentiation of malignant thyroid nodules: A systematic review and meta-analysis","volume":"89","author":"Kim","year":"2018","journal-title":"Clin. Endocrinol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Van Branteghem, C., Augenlicht, A., Demetter, P., Craciun, L., and Maenhaut, C. (2023). Unraveling the Roles of miR-204-5p and HMGA2 in Papillary Thyroid Cancer Tumorigenesis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241310764"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Saiselet, M., Gacquer, D., Spinette, A., Craciun, L., Decaussin-Petrucci, M., Andry, G., Detours, V., and Maenhaut, C. (2015). New global analysis of the microRNA transcriptome of primary tumors and lymph node metastases of papillary thyroid cancer. BMC Genom., 16.","DOI":"10.1186\/s12864-015-2082-3"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"854","DOI":"10.2353\/ajpath.2009.080523","article-title":"HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells","volume":"174","author":"Watanabe","year":"2009","journal-title":"Am. J. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.bbrc.2018.08.155","article-title":"High mobility group A2 (HMGA2) promotes EMT via MAPK pathway in prostate cancer","volume":"504","author":"Hawsawi","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Wang, X., Wang, J., and Wu, J. (2021). Emerging roles for HMGA2 in colorectal cancer. Transl. Oncol., 14.","DOI":"10.1016\/j.tranon.2020.100894"},{"key":"ref_16","first-page":"101","article-title":"HMGA2 facilitates epithelial-mesenchymal transition in renal cell carcinoma by regulating the TGF-beta\/Smad2 signaling pathway","volume":"39","author":"Kou","year":"2018","journal-title":"Oncol. Rep."},{"key":"ref_17","first-page":"5523","article-title":"The RET\/PTC3 oncogene: Metastatic solid-type papillary carcinomas in murine thyroids","volume":"58","author":"Powell","year":"1998","journal-title":"Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1210\/en.2008-0531","article-title":"Gene expression in RET\/PTC3 and E7 transgenic mouse thyroids: RET\/PTC3 but not E7 tumors are partial and transient models of human papillary thyroid cancers","volume":"149","author":"Burniat","year":"2008","journal-title":"Endocrinology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6347","DOI":"10.1073\/pnas.1131959100","article-title":"Specificity of short interfering RNA determined through gene expression signatures","volume":"100","author":"Semizarov","year":"2003","journal-title":"Proc. Nat. Am. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1261\/rna5160904","article-title":"Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs)","volume":"10","author":"Persengiev","year":"2004","journal-title":"RNA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1083\/jcb.200512110","article-title":"Transforming growth factor-beta employs HMGA2 to elicit epithelial-mesenchymal transition","volume":"174","author":"Thuault","year":"2006","journal-title":"J. Cell. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/cr.2009.5","article-title":"TGF-beta-induced epithelial to mesenchymal transition","volume":"19","author":"Xu","year":"2009","journal-title":"Cell Res"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3109\/03009734.2011.638729","article-title":"Tumor-promoting functions of transforming growth factor-beta in progression of cancer","volume":"117","author":"Miyazono","year":"2012","journal-title":"Ups J. Med. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1038\/sj.onc.1206602","article-title":"RET\/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase","volume":"22","author":"Knauf","year":"2003","journal-title":"Oncogene"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/sj.bjc.6604740","article-title":"Human thyroid tumours, the puzzling lessons from E7 and RET\/PTC3 transgenic mice","volume":"99","author":"Jin","year":"2008","journal-title":"Br. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Titov, S.E., Ivanov, M.K., Demenkov, P.S., Katanyan, G.A., Kozorezova, E.S., Malek, A.V., Veryaskina, Y.A., and Zhimulev, I.F. (2019). Combined quantitation of HMGA2 mRNA, microRNAs, and mitochondrial-DNA content enables the identification and typing of thyroid tumors in fine-needle aspiration smears. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-6154-7"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/cncy.20095","article-title":"HMGA2 gene expression analysis performed on cytologic smears to distinguish benign from malignant thyroid nodules","volume":"118","author":"Lappinga","year":"2010","journal-title":"Cancer Cytopathol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Su, L., Bryan, N., Battista, S., Freitas, J., Garabedian, A., D\u2019Alessio, F., Romano, M., Falanga, F., Fusco, A., and Kos, L. (2020). Identification of HMGA2 inhibitors by AlphaScreen-based ultra-high-throughput screening assays. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-75890-0"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/sj.cdd.4400410","article-title":"Suramin induced ceramide accumulation leads to apoptotic cell death in dorsal root ganglion neurons","volume":"5","author":"Gill","year":"1998","journal-title":"Cell Death Differ."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6269","DOI":"10.1002\/cam4.1877","article-title":"Suramin, screened from an approved drug library, inhibits HuR functions and attenuates malignant phenotype of oral cancer cells","volume":"7","author":"Kakuguchi","year":"2018","journal-title":"Cancer Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/0002-9343(94)90321-2","article-title":"Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer","volume":"97","author":"Ernest","year":"1994","journal-title":"Am. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0039-6109(16)41235-1","article-title":"Surgical treatment for thyroid cancer","volume":"57","author":"Edis","year":"1977","journal-title":"Surg. Clin. N. Am."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.critrevonc.2018.03.012","article-title":"Radioiodine refractory differentiated thyroid cancer","volume":"125","author":"Jin","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/(SICI)1098-2388(199901\/02)16:1<64::AID-SSU10>3.0.CO;2-U","article-title":"Anaplastic thyroid carcinoma: A therapeutic challenge","volume":"Volume 16","author":"Ain","year":"1999","journal-title":"Seminars in Surgical Oncology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1046\/j.1365-2265.2002.01640.x","article-title":"The sodium iodide symporter: Its pathophysiological and therapeutic implications","volume":"57","author":"Spitzweg","year":"2002","journal-title":"Clin. Endocrinol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"8113","DOI":"10.1158\/0008-5472.CAN-06-4026","article-title":"Human thyroid tumor cell lines derived from different tumor types present a common dedifferentiated phenotype","volume":"67","author":"Solis","year":"2007","journal-title":"Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Saiselet, M., Floor, S., Tarabichi, M., Dom, G., Hebrant, A., van Staveren, W.C., and Maenhaut, C. (2012). Thyroid cancer cell lines: An overview. Front. Endocrinol., 3.","DOI":"10.3389\/fendo.2012.00133"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/bjc.2017.403","article-title":"Silencing of HMGA2 reverses retardance of cell differentiation in human myeloid leukaemia","volume":"118","author":"Tan","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"11400","DOI":"10.1073\/pnas.0704372104","article-title":"Let-7 expression defines two differentiation stages of cancer","volume":"104","author":"Shell","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1016\/j.febslet.2007.06.072","article-title":"DNA architectural factor and proto-oncogene HMGA2 regulates key developmental genes in pluripotent human embryonic stem cells","volume":"581","author":"Li","year":"2007","journal-title":"FEBS Lett."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.omto.2019.01.007","article-title":"MAPK Inhibitors Enhance HDAC Inhibitor-Induced Redifferentiation in Papillary Thyroid Cancer Cells Harboring BRAF (V600E): An In Vitro Study","volume":"12","author":"Fu","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1210\/jc.2007-0097","article-title":"Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations","volume":"92","author":"Liu","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1172\/JCI89067","article-title":"Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine","volume":"126","author":"Nagarajah","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0303-7207(84)90087-X","article-title":"Factors controlling proliferation and differentiation of canine thyroid cells cultured in reduced serum conditions: Effects of thyrotropin, cyclic AMP and growth factors","volume":"36","author":"Pierre","year":"1984","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1172\/JCI46382","article-title":"Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation","volume":"121","author":"Chakravarty","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.18632\/aging.101143","article-title":"Effect of the micronutrient iodine in thyroid carcinoma angiogenesis","volume":"8","author":"Daniell","year":"2016","journal-title":"Aging"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1210\/jc.2006-2707","article-title":"BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism","volume":"92","author":"Durante","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_50","unstructured":"Cancer Genome Atlas Research Network (2014). Integrated genomic characterization of papillary thyroid carcinoma. Cell, 159, 676\u2013690."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.mce.2009.11.015","article-title":"Signal transduction in the human thyrocyte and its perversion in thyroid tumors","volume":"321","author":"Roger","year":"2010","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Li, D., Cao, Y., Wang, J., Yang, H., Liu, W., Cui, J., and Wu, W. (2021). Regulatory effect between HMGA2 and the Wnt\/beta-catenin signaling pathway in the carcinogenesis of sporadic colorectal tubular adenoma. Oncol. Lett., 22.","DOI":"10.3892\/ol.2021.13110"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Zhao, S., Zhang, Y., Bao, S., Jiang, L., Li, Q., Kong, Y., and Cao, J. (2024). A novel HMGA2\/MPC-1\/mTOR signaling pathway promotes cell growth via facilitating Cr (VI)-induced glycolysis. Chem. -Biol. Interact., 399.","DOI":"10.1016\/j.cbi.2024.111141"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.canlet.2016.04.005","article-title":"Elevated HMGA2 expression is associated with cancer aggressiveness and predicts poor outcome in breast cancer","volume":"376","author":"Wu","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/odi.12608","article-title":"HMGA2 is associated with the aggressiveness of tongue squamous cell carcinoma","volume":"23","author":"Zhang","year":"2017","journal-title":"Oral. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3892\/or.2015.4120","article-title":"STC2 overexpression mediated by HMGA2 is a biomarker for aggressiveness of high-grade serous ovarian cancer","volume":"34","author":"Wu","year":"2015","journal-title":"Oncol. Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3","DOI":"10.14218\/JCTP.2021.00018","article-title":"HMGA2: A Biomarker in Gynecologic Neoplasia","volume":"2","author":"Wei","year":"2022","journal-title":"J. Clin. Transl. Pathol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1016\/0303-7207(91)90018-N","article-title":"Human thyrotropin receptor gene: Expression in thyroid tumors and correlation to markers of thyroid differentiation and dedifferentiation","volume":"82","author":"Brabant","year":"1991","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0300-9084(99)80086-8","article-title":"Thyroid-specific gene expression in the multi-step process of thyroid carcinogenesis","volume":"84","author":"Ros","year":"1999","journal-title":"Biochimie"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/0960-0760(90)90439-R","article-title":"Suramin, a novel antitumor compound","volume":"37","author":"Stein","year":"1990","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_61","first-page":"93","article-title":"Combination chemotherapy with docetaxel, estramustine and suramin for hormone refractory prostate cancer","volume":"23","author":"Safarinejad","year":"2005","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/00001622-199709030-00011","article-title":"Prostate cancer","volume":"9","author":"Small","year":"1997","journal-title":"Curr. Opin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/02841869709109226","article-title":"Suramin in non-small cell lung cancer and advanced breast cancer. Two parallel phase II studies","volume":"36","author":"Mirza","year":"1997","journal-title":"Acta. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1038\/sj.bjc.6602650","article-title":"Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma","volume":"92","author":"Ord","year":"2005","journal-title":"Br. J. Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1200\/JCO.2001.19.13.3260","article-title":"for the New Approaches to Brain Tumor Therapy CNS Consortium. Toxicity, Efficacy, and Pharmacology of Suramin in Adults With Recurrent High-Grade Gliomas","volume":"19","author":"Grossman","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Wiedemar, N., Hauser, D.A., and Maser, P. (2020). 100 Years of Suramin. Antimicrob. Agents Chemother., 64.","DOI":"10.1128\/AAC.01168-19"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.actbio.2018.12.010","article-title":"Repurposing suramin for the treatment of breast cancer lung metastasis with glycol chitosan-based nanoparticles","volume":"84","author":"Cheng","year":"2019","journal-title":"Acta. Biomater."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s00280-010-1252-x","article-title":"Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer","volume":"66","author":"Lam","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s10585-014-9661-6","article-title":"Combined treatment with paclitaxel and suramin prevents the development of metastasis by inhibiting metastatic colonization of circulating tumor cells","volume":"31","author":"Singla","year":"2014","journal-title":"Clin. Exp. Metastasis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1080\/02713683.2017.1416146","article-title":"Corneal Neovascularization: A Combined Approach of Bevacizumab and Suramin Showed Increased Antiangiogenic Effect Through Downregulation of BFGF and P2X2","volume":"43","author":"Lopez","year":"2017","journal-title":"Curr. Eye Res."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Pfaffl, M.W. (2001). A new mathematical model for relative quantification in real-time RT\u2013PCR. Nucleic Acids Res., 29.","DOI":"10.1093\/nar\/29.9.e45"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/4\/1643\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:34:40Z","timestamp":1760027680000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/4\/1643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":71,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["ijms26041643"],"URL":"https:\/\/doi.org\/10.3390\/ijms26041643","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]}}}